Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) research hub
5 indexed studies · 0 currently recruiting
- ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, Batoclimab, for adults with a condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Researchers want to see if this medicine can stop CIDP symptoms from getting worse, compared to a dummy medicine. It's an important step to find better treatments.
Sweden · Spain · Norway - ongoing, recruitingPhase III and phase IV (Integrated)
Randomized, parallel study of subcutaneous versus intravenous immunoglobulin in treatment-naïve patients with chronic inflammatory demyelinating polyneuropathy
This study compares two ways of giving an important medicine for a nerve condition called CIDP. One way is an injection under the skin, and the other is through a drip into a vein. It looks at how well each method improves daily activities and muscle strength.
Denmark - active not recruitingPHASE2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
This study looks at a new drug, efgartigimod, for adults with CIDP, a nerve condition. It aims to see how safe and effective it is over a long time when given under the skin. Some participants might also try taking the drug less often.
United States · Austria · Belgium - ongoing, recruitingTherapeutic exploratory (Phase II)
An Open-Label Extension Study to Assess Long-term Safety and Tolerability of Batoclimab in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study looks at the long-term safety of a new medicine called Batoclimab for adults with a nerve condition called CIDP. It mainly checks for any side effects and how well people tolerate the treatment over time.
Belgium · Denmark · Italy - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine called NVG-2089 for a nerve condition called CIDP. It's looking at how safe the medicine is, if people can tolerate it, and if it helps improve CIDP symptoms. It includes people new to treatment and those who've tried other things.
Spain · France · Poland